布雷美拉诺肽 PT-141 / Bremelanotide

PT-141 is the only FDA-approved drug that works on sexual desire by targeting the brain rather than the genitals — and that distinction matters more than it might sound. Approved under the brand name Vyleesi in 2019, it's a synthetic melanocortin receptor agonist used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women, and it's prescribed off-label for erectile dysfunction (ED) in men.^[1]

The compound is a 7-amino acid synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Its generic name is bremelanotide. Palatin Technologies developed it originally as a nasal spray for ED before pivoting to subcutaneous injection and the HSDD indication.^[2]

If you've tried PDE5 inhibitors like sildenafil or tadalafil and found they don't address the desire side of things — or if you're a woman with HSDD looking for an FDA-approved option — PT-141 is one of the very few compounds that has actually been through Phase 3 trials for this specific problem.^[1]

Key Takeaways

• PT-141 (bremelanotide / Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women — the only on-demand, centrally-acting option in this class.
• It works by activating MC3R and MC4R melanocortin receptors in the central nervous system, driving desire from the brain rather than increasing genital blood flow.

Administered as a subcutaneous injection approximately 45 minutes before sexual activity; effects last several hours.

Most common side effects are nausea and flushing, both dose-dependent and typically transient.

Also used off-label for erectile dysfunction in men, with early-phase clinical data supporting efficacy.

Class	Melanocortin Receptor Agonist
Mechanism	MC3R and MC4R agonism in the central nervous system
FDA Status	Approved — Vyleesi (bremelanotide), 2019
Approved Indication	Acquired, generalized HSDD in premenopausal women
Administration	Subcutaneous injection, on-demand
Typical Dose	1.75 mg subcutaneous injection, 45 min before activity
Amino Acids	7
Primary Uses	HSDD (women), erectile dysfunction (off-label)
Developed By	Palatin Technologies / AMAG Pharmaceuticals

---

Almost every drug used for sexual dysfunction works peripherally — it relaxes smooth muscle, increases blood flow to the genitals, or adjusts hormone levels. PT-141 takes a different route entirely. It acts in the brain.

That's not a marketing angle. It's a genuine pharmacological distinction with real clinical consequences. A man who can achieve an erection mechanically but lacks desire doesn't have a blood flow problem. A woman with HSDD whose distress comes from the absence of wanting sex doesn't need a vasodilator. PT-141 was designed for exactly these situations.

The central mechanism in plain English

PT-141 activates melanocortin receptors (specifically MC3R and MC4R) that are expressed primarily in the central nervous system. In animal studies, this activation increased sexual motivation and produced penile erections by stimulating hypothalamic neurons — not by acting on genital tissue directly. The hypothalamic pathway is the same one involved in the natural drive for sexual activity.^[3]

This also explains why PT-141 can work in situations where PDE5 inhibitors fail. In a clinical study of men with ED — including those who had not responded to sildenafil — PT-141 still produced significant erectile responses.^[3] That's a meaningful finding for a subset of patients who've run out of conventional options.

---

PT-141 is a synthetic analog of alpha-MSH, a naturally occurring neuropeptide. It binds to melanocortin receptors — specifically MC3R and MC4R — which are concentrated in the hypothalamus and other regions of the brain involved in sexual motivation and arousal.^[3]

When those receptors are activated, they trigger downstream neural signaling that increases sexual desire and, in men, initiates the erectile response through central pathways. In rat studies, systemic PT-141 administration activated neurons in the hypothalamus (measured by c-Fos immunoreactivity), and those same hypothalamic neurons have direct neural connections to the corpus cavernosum — the erectile tissue of the penis.^[3] That's the mechanistic link: brain activation → spinal cord signaling → genital response.

In women, the mechanism is analogous: central melanocortin activation appears to modulate the motivational component of sexual response. The Phase 3 trials for HSDD measured this not as a physiological endpoint but as patient-reported desire and distress — because that's what actually matters clinically.^[1]

One important note: PT-141 does not affect sex hormone levels. It isn't a testosterone booster or an estrogen modulator. Its effect is purely through receptor-level signaling in the CNS.

---

FDA Approval: HSDD in Premenopausal Women

Bremelanotide earned FDA approval in June 2019 based on two Phase 3 randomized, placebo-controlled trials in premenopausal women with acquired, generalized HSDD. AMAG Pharmaceuticals commercialized the drug in the US following an out-licensing agreement with Palatin Technologies.^[1]

Both trials used patient-reported outcomes — specifically the Female Sexual Function Index desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) — as primary endpoints. Women receiving bremelanotide 1.75 mg showed statistically significant improvements in sexual desire and reductions in distress compared to placebo.^[1] The effect size was modest in absolute terms, but this is a condition with very few approved treatment options, and the on-demand dosing model is a practical advantage over daily medications.

Erectile Dysfunction: Early-Phase Data

The original development program for PT-141 focused on ED. In a Phase 2 study in men with psychogenic or organic ED — including a subset who had not responded to sildenafil — intranasal PT-141 produced significant improvements in erectile function compared to placebo.^[3] By September 2003, Palatin had completed a Phase 2b trial in ED patients, with Phase 3 planning underway at the time of early publications.^[2]

The ED development program ultimately did not advance to FDA approval under the current subcutaneous formulation, but the compound is used off-label for this indication through compounding pharmacies. The early-phase data is real; what's missing is a large Phase 3 RCT with the approved subcutaneous formulation in men.

The Melanocortin System More Broadly

PT-141's approval sits within a broader story about melanocortin receptors as therapeutic targets. The same year bremelanotide was approved for HSDD, another melanocortin-targeting drug was approved for erythropoietic protoporphyria. In 2020, setmelanotide — which targets the central melanocortin system — was approved for specific forms of genetic obesity.^[4] This isn't a niche receptor system; it's an active area of drug development with multiple approved agents.

---

The FDA-approved dose for bremelanotide is 1.75 mg administered as a single subcutaneous injection approximately 45 minutes before anticipated sexual activity.^[1] This is an on-demand regimen — you don't take it daily. The label recommends no more than one dose in 24 hours and limits use to approximately 8 doses per month [VERIFY exact monthly limit from prescribing information].

1.75 mg FDA-approved subcutaneous dose — administered on-demand, 45 min before sexual activity

Injection sites include the abdomen or thigh. The drug comes in a single-use autoinjector (the Vyleesi device), which makes self-administration straightforward. Rotate injection sites to minimize local reactions.

For off-label use in men with ED, practitioners typically use the same 1.75 mg dose — the same dose established as therapeutic in clinical trials that tested 0.75, 1.25, and 1.75 mg subcutaneously — though some protocols report starting at 1 mg and titrating up based on response and tolerability. These off-label ranges aren't derived from a completed Phase 3 trial in men — they reflect practitioner consensus and early-phase trial data.

Off-label use in men

The 1.75 mg subcutaneous dose is FDA-approved only for HSDD in premenopausal women. Use in men with erectile dysfunction is off-label. Early clinical data supports efficacy, but there is no approved male dosing protocol. If you're a man considering PT-141, this needs to be a conversation with a prescribing provider — not a self-directed decision.

---

PT-141's side effect profile is well-characterized from Phase 3 trials. The good news: nothing here is severe for most people. The practical reality: nausea is common enough that it affects tolerability for some users.

At the time of dosing and in the first few hours:

• Nausea — the most commonly reported side effect in clinical trials; typically peaks in the 1–2 hours post-injection and resolves on its own. Dose-dependent. Taking it on an empty stomach can make it worse.^[1]
• Flushing — facial and neck flushing reported in a meaningful proportion of trial participants; usually brief and not dangerous.^[1]
• Transient blood pressure increase — bremelanotide can cause a temporary rise in blood pressure, typically peaking around 12 minutes post-dose and resolving within 12 hours.^[1] This is clinically significant for anyone with cardiovascular risk factors. The FDA label includes a contraindication for patients with known cardiovascular disease [VERIFY exact contraindication language].
• Injection site reactions — mild redness, bruising, or tenderness at the injection site; rotate sites to reduce frequency.

Less common:

• Headache — reported in some trial participants; generally mild.^[1]
• Hyperpigmentation — focal skin darkening with repeated use has been reported, particularly on the face, gums, and breasts. This is a class effect of melanocortin agonists and is worth knowing about before starting long-term use [VERIFY frequency data from prescribing information].

What warrants a call to your provider: Chest pain, significant blood pressure elevation, or skin changes that progress or spread. Nausea and flushing that are severe enough to interfere with the intended effect of the drug — that's a tolerability conversation worth having, because dose timing and food intake can sometimes help.

---

• Long-term safety data in men — the off-label ED use doesn't have the same evidence base as the approved female HSDD indication. Phase 2 data is encouraging, but it's not Phase 3.
• Efficacy in postmenopausal women — the FDA approval is specifically for premenopausal women. Whether it works comparably in postmenopausal women is not established by the approved trial data.
• Head-to-head comparisons with flibanserin — flibanserin (Addyi) is the other FDA-approved HSDD treatment, taken daily. There are no direct comparison trials. Choosing between them involves practical factors (on-demand vs. daily, route of administration, side effect profiles) that haven't been formally studied head-to-head.
• Cardiovascular safety at scale — the blood pressure effect is real and documented. Long-term cardiovascular outcomes data comparable to what exists for some other drug classes doesn't exist for bremelanotide.
• Efficacy for situational or relationship-driven low desire — the approval is for "acquired, generalized" HSDD. If low desire is situational (specific partner, specific context) or primarily relationship-driven, the evidence base doesn't speak to that population directly.

---

PT-141 / bremelanotide is FDA-approved and commercially available in the US under the brand name Vyleesi. It requires a prescription.

Access status — March 2026

Bremelanotide (Vyleesi) is FDA-approved and available by prescription in the US. It is also available through licensed compounding pharmacies, which may offer it at lower cost than the branded product. A valid prescription from a licensed provider is required for either route. Telehealth platforms that specialize in sexual health frequently prescribe it.

The branded Vyleesi product is manufactured and distributed by AMAG Pharmaceuticals. Compounded versions of bremelanotide are available through 503A compounding pharmacies, which can compound it for individual patients with a valid prescription. Cost is a real consideration — the branded product is expensive, and insurance coverage is inconsistent. Compounded versions are typically more affordable.

If you're looking for a clinic or telehealth provider who prescribes PT-141, the MyPeptideMatch clinic finder can help you locate licensed providers in your area.

---

PT-141 sits within the melanocortin receptor agonist class, which also includes setmelanotide — approved for genetic obesity via central melanocortin pathway activation — and earlier compounds like Melanotan II, which is PT-141's precursor and is not FDA-approved. If you're interested in the broader melanocortin system and its therapeutic applications, the setmelanotide encyclopedia page covers how the same receptor family is being targeted for metabolic disease.

For men specifically weighing PT-141 against other ED options, the mechanism difference from PDE5 inhibitors is the key variable. PT-141 is worth considering when desire is the issue, when PDE5 inhibitors haven't worked, or when a centrally-acting option is preferred. It's not a replacement for sildenafil or tadalafil in straightforward vasculogenic ED.

PT-141 vs. Other Sexual Dysfunction Treatments

Parameter	PT-141 (Bremelanotide)	Sildenafil (Viagra)	Flibanserin (Addyi)
Mechanism	Central: MC3R/MC4R agonism	Peripheral: PDE5 inhibition	Central: Serotonin/dopamine modulation
FDA-approved indication	HSDD (premenopausal women)	Erectile dysfunction (men)	HSDD (premenopausal women)
Dosing schedule	On-demand injection	On-demand oral	Daily oral
Works on desire?	Yes	No	Yes
Alcohol interaction	No restriction	Caution advised	Contraindicated
Available for men?	Off-label	Yes (approved)	Not studied

---